Dr. Dimopoulos on the Utility of Zanubrutinib in Waldenström Macroglobulinemia

Meletios A. Dimopoulos, MD, professor and chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University Athens School of Medicine, in Athens, Greece, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.

In August 2018, the combination of ibrutinib (Imbruvica) and rituximab (Rituxan) became the first regimen to receive regulatory approval for the treatment of patients with Waldenström macroglobulinemia, says Dimopoulos.

Zanubrutinib is a next-generation BTK inhibitor that could maximize BTK occupancy and minimize off-target inhibition that is associated with earlier generation BTK inhibitors, explains Dimopoulos.

Additionally, zanubrutinib appears to have favorable drug-drug interaction properties, which could aid in the administration of this agent, concludes Dimopoulos.